Table 3.

Relationship between GlycA levels and psoriasis skin disease severity assessed by multivariable linear regression analysis.

A: GlycA vs. body surface area in the PENN Cohort
Model	β (p value)
Unadjusted	0.29 (0.002)
Adjusted for age and gender	0.34 (0.001)
Adjusted for age, gender and FRS	0.26 (0.007)
Adjusted for age, gender, FRS and BMI	0.25 (0.01)
Adjusted for age, gender, FRS, BMI, SBP, LDL-C, HDL-C, HOMA-IR	0.21 (0.01)

B: GlycA vs. body surface area in the NIH Cohort
Model	β (p value)
Unadjusted	0.42 (<0.001)
Adjusted for age and gender	0.42 (<0.001)
Adjusted for age, gender and FRS	0.42 (<0.001)
Adjusted for age, gender, FRS and BMI	0.41 (<0.001)
Adjusted for age, gender, FRS, BMI, SBP, LDL-C, HDL-C, HOMA-IR	0.40 (<0.001)

C: GlycA vs. Psoriasis Area and Severity Index score in the NIH Cohort
Model	β (p value)
Unadjusted	0.52 (<0.001)
Adjusted for age and gender	0.53 (<0.001)
Adjusted for age, gender and FRS	0.52 (<0.001)
Adjusted for age, gender, FRS and BMI	0.50 (<0.001)
Adjusted for age, gender, FRS, BMI, SBP, LDL-C, HDL-C, HOMA-IR	0.49 (<0.001)

All values reported as ‘Standardized β (p value)’.

FRS: Framingham Risk Score, BMI: Body Mass Index, SBP: Systolic Blood Pressure, HOMA-IR: Homeostasis Model Assessment of Insulin Resistance.